Cargando…

Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial

OBJECTIVES: Canagliflozin (CANA), a kind of sodium-glucose cotransporter-2 (SGLT-2) inhibition, study in which the role of CANA monotherapy in polycystic ovary syndrome (PCOS) has been investigated, and it could become a novel option in the PCOS treatment. Nevertheless, trials focused on SGLT-2 comb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jiaqi, Xing, Chuan, Cheng, Xiangyi, He, Bing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486461/ https://www.ncbi.nlm.nih.gov/pubmed/36147577 http://dx.doi.org/10.3389/fendo.2022.1003238

Ejemplares similares

Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome
por: Xing, Chuan, et al.
Publicado: (2022)

Sodium-glucose cotransporter-2 inhibitors for improving endocrine and metabolic profiles in overweight and obese individuals with polycystic ovary syndrome: a meta-analysis protocol
por: Zhang, Jiaqi, et al.
Publicado: (2022)

Metformin combined with spironolactone vs. metformin alone in polycystic ovary syndrome: a meta-analysis
por: Zeng, Huamin, et al.
Publicado: (2023)

Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis
por: Peng, Qingjie, et al.
Publicado: (2023)

The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary Syndrome
por: Sathyapalan, Thozhukat, et al.
Publicado: (2019)

Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin
por: Trouva, Anastasia, et al.
Publicado: (2022)

Acupuncture combined with metformin versus metformin alone to improve pregnancy rate in polycystic ovary syndrome: A systematic review and meta-analysis
por: Chen, Xin, et al.
Publicado: (2022)

Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial
por: Wen, Qing, et al.
Publicado: (2023)

The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome
por: Javed, Zeeshan, et al.
Publicado: (2020)

Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome
por: Ma, Rui-Lin, et al.
Publicado: (2021)

PMON208 METFORMIN, SPIRONOLACTONE AND ORAL CONTRACEPTIVES IN POLYCYSTIC OVARY SYNDROME: A NETWORK META-ANALYSIS
por: Rodriguez-Gutierrez, Rene, et al.
Publicado: (2022)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
por: Wilding, J P H, et al.
Publicado: (2013)

An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials
por: Sun, Jie, et al.
Publicado: (2015)

Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial
por: Cai, Hongyu, et al.
Publicado: (2023)

Effects of TCM on polycystic ovary syndrome and its cellular endocrine mechanism
por: Chen, Huize, et al.
Publicado: (2023)

Study on the Effect of Berberine, Myoinositol, and Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomised Study
por: Mishra, Neha, et al.
Publicado: (2022)

Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance
por: Xie, Yidong, et al.
Publicado: (2021)

A review of the hormones involved in the endocrine dysfunctions of polycystic ovary syndrome and their interactions
por: Emanuel, Rebecca H. K., et al.
Publicado: (2022)

Endocrine and metabolic interactions in healthy pregnancies and hyperinsulinemic pregnancies affected by polycystic ovary syndrome, diabetes and obesity
por: Neven, Adriana C. H., et al.
Publicado: (2023)

Effects of metformin use in pregnant patients with polycystic ovary syndrome
por: Kumar, Pratap, et al.
Publicado: (2012)

Role of Metformin in Polycystic Ovary Syndrome (PCOS)-Related Infertility
por: Attia, Ghalia M, et al.
Publicado: (2023)

Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis
por: Hu, Yan, et al.
Publicado: (2023)

Characteristics and possible mechanisms of metabolic disorder in overweight women with polycystic ovary syndrome
por: Yu, Jin, et al.
Publicado: (2023)

Time-restricted feeding improves metabolic and endocrine profiles in mice with polycystic ovary syndrome
por: Han, Yan, et al.
Publicado: (2022)

Comparison of Serum Vitamin B12 Levels Among Drug-Naïve and Metformin-Treated Patients With Polycystic Ovary Syndrome
por: Kamrul-Hasan, ABM, et al.
Publicado: (2022)

Metformin Inhibits Follicle-Stimulating Hormone (FSH) Action in Human Granulosa Cells: Relevance to Polycystic Ovary Syndrome
por: Rice, Suman, et al.
Publicado: (2013)

Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease
por: Leonhard, Wouter N., et al.
Publicado: (2019)

Comparison of Clinical, Metabolic and Hormonal Effects of Metformin Versus Combined Therapy of Metformin With Myoinositol Plus D-Chiro-Inositol in Women With Polycystic Ovary Syndrome (PCOS): A Randomized Controlled Trial
por: Bahadur, Anupama, et al.
Publicado: (2021)

Effect of Metformin on Serum Ferritin Level in Women with Polycystic Ovary Syndrome
por: Behradmanesh, S, et al.
Publicado: (2011)

Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome
por: Yang, Young-Mo, et al.
Publicado: (2015)

Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome
por: Shahebrahimi, Karoon, et al.
Publicado: (2016)

Clinical outcome of various metformin treatments for women with polycystic ovary syndrome
por: Matsuzaki, Toshiya, et al.
Publicado: (2017)

Impaired Prolactin-Lowering Effects of Metformin in Women with Polycystic Ovary Syndrome
por: Krysiak, Robert, et al.
Publicado: (2023)

SUN-022 Metformin-Fish Oil Adjunct Therapy Improves apoB-Remnant Lipoprotein and Triglyceride Levels in Women with Polycystic Ovary Syndrome
por: Proctor, Ethan, et al.
Publicado: (2020)

Metformin Improves the Hepatic Steatosis Index in Non-Obese Patients with Polycystic Ovary Syndrome
por: Riemann, Annika, et al.
Publicado: (2022)

Reactive Hypoglycemia From Metformin Immediate-Release Monotherapy Resolved by a Switch to Metformin Extended-Release: Conceptualizing Their Concentration-Time Curves
por: Akram, Ayesha
Publicado: (2021)

The Effect of Metformin on Polycystic Ovary Syndrome in Overweight Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Guan, Yuanyuan, et al.
Publicado: (2020)

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes
por: Liu, Jia, et al.
Publicado: (2017)

Ovulation induction by metformin among obese versus non-obese women with polycystic ovary syndrome
por: Al-Ruthia, Yazed Sulaiman, et al.
Publicado: (2017)

Metformin: Focus on Melanoma
por: Jaune, Emilie, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k2b7ql7ov8u9vnbhriu43d7tlg